HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.

Abstract
PD-1 blockade represents a major therapeutic avenue in anticancer immunotherapy. Delineating mechanisms of secondary resistance to this strategy is increasingly important. Here, we identified the deleterious role of signaling via the type I interferon (IFN) receptor in tumor and antigen presenting cells, that induced the expression of nitric oxide synthase 2 (NOS2), associated with intratumor accumulation of regulatory T cells (Treg) and myeloid cells and acquired resistance to anti-PD-1 monoclonal antibody (mAb). Sustained IFNβ transcription was observed in resistant tumors, in turn inducing PD-L1 and NOS2 expression in both tumor and dendritic cells (DC). Whereas PD-L1 was not involved in secondary resistance to anti-PD-1 mAb, pharmacological or genetic inhibition of NOS2 maintained long-term control of tumors by PD-1 blockade, through reduction of Treg and DC activation. Resistance to immunotherapies, including anti-PD-1 mAb in melanoma patients, was also correlated with the induction of a type I IFN signature. Hence, the role of type I IFN in response to PD-1 blockade should be revisited as sustained type I IFN signaling may contribute to resistance to therapy.
AuthorsNicolas Jacquelot, Takahiro Yamazaki, Maria P Roberti, Connie P M Duong, Miles C Andrews, Loic Verlingue, Gladys Ferrere, Sonia Becharef, Marie Vétizou, Romain Daillère, Meriem Messaoudene, David P Enot, Gautier Stoll, Stefano Ugel, Ilaria Marigo, Shin Foong Ngiow, Aurélien Marabelle, Armelle Prevost-Blondel, Pierre-Olivier Gaudreau, Vancheswaran Gopalakrishnan, Alexander M Eggermont, Paule Opolon, Christophe Klein, Gabriele Madonna, Paolo A Ascierto, Antje Sucker, Dirk Schadendorf, Mark J Smyth, Jean-Charles Soria, Guido Kroemer, Vincenzo Bronte, Jennifer Wargo, Laurence Zitvogel
JournalCell research (Cell Res) Vol. 29 Issue 10 Pg. 846-861 (Oct 2019) ISSN: 1748-7838 [Electronic] England
PMID31481761 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • B7-H1 Antigen
  • CD274 protein, human
  • Interferon Type I
  • Programmed Cell Death 1 Receptor
  • Nitric Oxide Synthase Type II
Topics
  • Animals
  • Antibodies, Monoclonal (immunology, pharmacology, therapeutic use)
  • B7-H1 Antigen (metabolism)
  • Cell Line, Tumor
  • Dendritic Cells (cytology, metabolism)
  • Drug Resistance, Neoplasm
  • Humans
  • Interferon Type I (metabolism)
  • Kaplan-Meier Estimate
  • Melanoma (drug therapy, mortality, pathology)
  • Mice
  • Mice, Inbred C57BL
  • Neoplasms (drug therapy, mortality, pathology)
  • Nitric Oxide Synthase Type II (metabolism)
  • Programmed Cell Death 1 Receptor (immunology)
  • Signal Transduction (drug effects)
  • T-Lymphocytes, Regulatory (cytology, immunology, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: